Aratana Therapeutics (PETX): Cutting PT - Jefferies
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Jefferies analyst, David Gu, reiterated his Buy rating on shares of Aratana Therapeutics (NASDAQ: PETX) but cut his price target to $11 noting that Entyce and Nocita remain on track and are the key drivers of valuation.
AT-018 development in recurrent atopic dermatitis was discontinued, and he sees modest impact on the shares as due to the asymmetrical upside for this underthe-radar asset. That said, he cut the price target to $11 from $13 to reflect development updates.
Shares of Aratana Therapeutics closed at $7.94 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Facebook (FB) Q4 Estimates, PT Raised At Jefferies
- Bank of Marin Bancorp (BMRC) PT Raised to $70 at FIG Partners Following 4Q Report
- Sanchez Energy (SN) PT Raised to $16 at FBR Capital; Reiterates Outperform
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!